Manoj Chevli

Jan 26, 2025 | tandfonline.com | Francesco Passamonti |Siddhi Korgaonkar |Rohan Parikh |Manoj Chevli

ABSTRACTAim Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX). Patients & Methods This study was a retrospective, noninterventional medical record review of patients in Canada, Germany, and the United Kingdom (UK). A total of 70 physicians (primarily hematologist-oncologists [78.6%]) provided data for 196 eligible patients.